Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients (COMMUNITY)
Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
Sponsor: Amgen
A PHASE3 clinical study on COVID-19, this trial is completed. The trial is conducted by Amgen and has accumulated 14 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2022 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .